PATENT CLAIM ANALYSIS

Application Number: 16016250
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2018-12
Patent Classification: ["514", "279000"]

Abstract:
The disclosure provides sustained-release buprenorphine formulations that produce therapeutic plasma concentration levels of buprenorphine in patients to treat opioid use disorder.

Claim (Index 1):
A method of treating moderate-to-severe opioid use disorder in an injection drug patient in need thereof, the method comprising subcutaneously administering a buprenorphine composition once per month for at least six months to the injection drug patient; wherein the buprenorphine composition comprises: (i) about 300 mg buprenorphine free base at 18 wt %; (ii) about 32 wt % of a 50:50 poly(DL-lactide-co-glycolide) copolymer having a carboxy terminal group and a weight average molecular weight of about 9,000 Daltons to about 19,000 Daltons; and (iii) about 50 wt % of N-methyl-2-pyrrolidone.

Metadata:
- Claim Count in Document: 110.0
- Percentile: 94.0
- Lexical Diversity: 1.04762
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15623191', '13836134', '15857507', '14610818', '15334000']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7858978856381087
- 35 USC 102 Novelty (BERT): 0.5144923956481396
- Combined Prediction Score: 0.7587573366391118
- Mean Citation Score: 302.2236400000001
- Max Citation Score: 315.9235
- Similarity Product: 280.3647219250202

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test